|
Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study. |
|
|
Consulting or Advisory Role - Celgene |
|
|
No Relationships to Disclose |
|
|
Employment - InfectoPharm (I) |
|
|
Research Funding - Celgene |
|
|
Honoraria - Amgen; Celgene; EUSA Pharma; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Amgen; Celgene; EUSA Pharma; Novartis; Roche |
|
|
Leadership - DBV Technologies (I); lysogen (I); Medday Pharmaceuticals (I) |
|
Consulting or Advisory Role - Celgene; Jazz Pharmaceuticals; Novartis; SERVIER |
Research Funding - Jazz Pharmaceuticals (Inst); Shire (Inst) |
Travel, Accommodations, Expenses - Jazz Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
|
|
Consulting or Advisory Role - Amgen; Baxalta/Shire; Jazz Pharmaceuticals; Novartis; SERVIER |
Speakers' Bureau - Amgen; Baxalta/Shire; Jazz Pharmaceuticals; Novartis; SERVIER |
Research Funding - Astellas Pharma |
Travel, Accommodations, Expenses - Jazz Pharmaceuticals; Novartis; SERVIER |
|
|
Speakers' Bureau - Novartis; Vifor Pharma |
Travel, Accommodations, Expenses - Bayer |
|
|
Consulting or Advisory Role - Bluebird Bio; Jazz Pharmaceuticals |
Speakers' Bureau - Chimerix |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
Marry M. Van Den Heuvel-Eibrink |
Consulting or Advisory Role - Celgene |
|
|
No Relationships to Disclose |